Aptose biosciences meets nasdaq minimum bid price compliance

San diego and toronto, march 17, 2025 (globe newswire) -- aptose biosciences inc. (“aptose” or the “company”) (nasdaq: apto, tsx: aps), a clinical-stage precision oncology company developing the tuspetinib (tus)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (aml), today announced that it received a written notification from the listing qualifications department of the nasdaq stock market, llc (“nasdaq”) notifying the company that it is in compliance with nasdaq's minimum bid price requirement. on march 14, 2025, nasdaq confirmed that, for ten consecutive business days, the closing bid price of the company's common shares has been $1.00 per share or greater.
NDAQ Ratings Summary
NDAQ Quant Ranking